Status:
WITHDRAWN
Use of Morphine Gel Topically in Patients With Stage 2-3 Wounds
Lead Sponsor:
Banner Health
Conditions:
Wounds
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Morphine gel applied topically to wounds will reduce wound pain and decrease patients use of oral and intravenous pain medications, therefore reducing side effects.
Detailed Description
Patients will be randomized to receive either placebo (versa base gel) or morphine gel to wound. Patients receiving morphine gel will have a decrease in pain score and use less oral/intravenous pain m...
Eligibility Criteria
Inclusion
- Signed and dated consent form \& HIPAA
- \>/= 18 yo
- Single stage 2-3 wound evaluated by our wound care team
- Alert and oriented (thinking ability clear and intact, physician approval)
- English language proficiency, likely to be able to participate in all scheduled evaluations
Exclusion
- Allergy to morphine, codeine, or versa base
- pts taking medications for acute condition, other than for the wound pain (can be taking chronic pain meds if current dose stable for past 3 mo)
- Patients with neuropathies
- Patients with respiratory conditions
- Patients that are pregnant
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2010
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00755989
Start Date
April 1 2009
End Date
April 1 2010
Last Update
July 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Banner Good Samaritan Medical Center
Phoenix, Arizona, United States, 85006